Bookmark and Share
Acenocoumarol (CID 54676537) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(7)
 
 
Inactive(883)
 
 
Inconclusive(10)
 
 
Unspecified(37)
 
 
Top Targets:
7TM GPCR Srx(23)
 
 
7TM GPCR Srsx(22)
 
 
alkPPc(12)
 
 
Bcl-2 like(12)
 
 
NR LBD PPAR(12)
 
 
 
 
BioAssay Types:
Screening(565)
 
 
 
 
 
Confirmatory(271)
 
 
 
 
 
Literature(57)
 
 
 
 
Summary(24)
 
 
 
BioActivity Types:
Potency(233)
 
 
 
 
 
IC50(43)
 
 
 
 
EC50(7)
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 853    Data Row: 937   Total Pages: 47   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103532358]
IC50 0.77Inhibition of rat microsomal VKER [AID293981, Type: Literature]
View
2
[SID144203981]
Potency-Replicate_1 7.1669qHTS assay for small molecule disruptors of the mitochondrial membrane potential [AID720635, Type: confirmatory]
View
3
[SID144203981]
Ratio Potency (uM) 8.35601qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary [AID720637, Type: summary]
View
4
[SID17385821]
Non-Nucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity HTS Single Point (MLSMR Library) [AID841, Type: screening]
View
5
[SID48415501]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
6
[SID17385821]
CYP2C9 Assay [AID777, Type: screening]cytochrome P450 2C9 precursor [Homo sapiens] [gi:13699818]
View
7
[SID144203981]
Ratio Potency (uM) qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary [AID743140, Type: summary]peroxisome proliferator activated receptor gamma [Homo sapiens] [gi:216409692]
View
8
[SID103532358]
Percent relaxation using isolated guinea pig trachea. [AID80624, Type: Literature]
View
9
[SID103532358]
Percent relaxation of isolated guinea pig trachea. [AID80631, Type: Literature]
View
10
[SID103532358]
Displacement of radiolabeled warfarin from fatty acid-free human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy [AID604741, Type: Literature]Serum albumin [gi:113576]
View
11
[SID103532358]
Displacement of radiolabeled dansylsarcosine from fatty acid-free human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy [AID604742, Type: Literature]Serum albumin [gi:113576]
View
12
[SID103532358]
Displacement of radiolabeled warfarin from fatty acid containing human serum albumin site 1 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy [AID604743, Type: Literature]Serum albumin [gi:113576]
View
13
[SID103532358]
Displacement of radiolabeled dansylsarcosine from fatty acid containing human serum albumin site 2 in phosphate buffer at pH 7.4 at 12 uM by fluorescence spectroscopy [AID604744, Type: Literature]Serum albumin [gi:113576]
View
14
[SID103532358]
Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data [AID625295, Type: Literature]
View
15
[SID103532358]
Metabolic stability in human liver microsomes assessed as intrinsic clearance per mg of protein [AID411793, Type: Literature]
View
16
[SID103532358]
Volume of distribution at steady state in human at 25 mg, iv [AID419495, Type: Literature]
View
17
[SID103532358]
Protein binding in human plasma at 25 mg, iv [AID419496, Type: Literature]
View
18
[SID103532358]
Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] [AID1079931, Type: Literature]
View
19
[SID103532358]
Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] [AID1079932, Type: Literature]
View
20
[SID103532358]
Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source] [AID1079933, Type: Literature]
View